Teleflex Incorporated

Valuation Analysis

About the Company

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the

Teleflex Incorporated Stock at a Glance

Teleflex Incorporated (TFX) is currently trading at $130.48 with a market capitalization of $5.8B. The trailing P/E ratio stands at 1864x, with a forward P/E of 12.37x. The 52-week range spans from $100.18 to $139.67; the current price is 6.6% below the yearly high. Year-over-year revenue growth stands at +32.3%.

💰 Dividend

Teleflex Incorporated pays an annual dividend of $1.36 per share, representing a yield of 1.04%. The payout ratio stands at 2266.67%. The elevated payout ratio reflects a mature dividend policy.

📊 Analyst Rating

9 analysts rate Teleflex Incorporated (TFX) on consensus: Hold. The average price target is $145.89, implying +11.81% from the current price. Analyst price targets range from $135.00 to $160.00.

Teleflex Incorporated: The Investment Case in Detail

Teleflex Incorporated (TFX) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 32.3% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.16, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.37x is meaningfully below the trailing 1864x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (8.25%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Teleflex Incorporated?

Compare top-rated brokers — low fees, trusted providers, fully regulated.